Indian drug regulator on Tuesday allowed the vaccine manufacturer Serum Institute of India to enrolL children between seven and 11 years of age for its COVID-19 vaccine trial, as per sources informed Reuters.
Earlier this month, the CEO of Serum Institute of India Adar Poonawalla said that he is confident that Covovax, another COVID-19 vaccine being manufactured by his company in India, will be launched in October for adults and for children by the first quarter of 2022.
So far, two Indian vaccine manufactures — Bharat Biotech (Covaxin) and Zydus Cadila (ZyCoV-D) — have already started their trials on children.
With the administration of 1,02,22,525 vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage crossed the landmark of 87 Cr (87,07,08,636) as per provisional reports till 7 am today. This has been achieved through 84,62,957 sessions.
The recovery of 26,030 patients in the last 24 hours has increased the cumulative tally of recovered patients (since the beginning of the pandemic) to 3,29,58,002.
Consequently, India’s recovery rate stands at 97.81%. Recovery Rate is currently at its highest peak since March 2020.
The Active Caseload is presently 2,92,206, which is the lowest in 192 days. Active cases presently constitute 0.87% of the country’s total Positive Cases.